Michael J. Weickert - CEO
Michael has been in biotech for over 25 years, as CEO of Sonescence and SEA Medical Systems, CBO of Strategent Life Sciences, Corium, and Therashock, VP of development at SciDose and Auspex, and Senior Program Executive or Manager at Nektar and Ligand. Key roles included raising capital, establishing and maintaining business partnerships, building teams, and developing new products. He raised Seed through Series C capital and established partnerships worth more than $175 Million. Michael has driven oncology product development including during the Phase III/NDA for Targretin, and business planning for drug delivery of Leuprolide, Paclitaxel and Irinotecan. He obtained Orphan Drug and Fast Track designations for products in US and EU. Dr. Weickert received his Ph.D. in Genetics from the University of Wisconsin and worked at the National Cancer Institute of NIH. He holds 7 issued and 19 pending patents and has 23 publications.
Luc G. Berthiaume - Co-founder and CSO
Luc is a professor of cell biology at University of Alberta with 21 years of experience studying protein fatty acylation. He received his PhD from the Université de Sherbrooke and completed his Post-Doctoral Fellowship at the Memorial Sloan-Kettering Cancer Centre. He has more than 40 publications and 3 patents published or pending. Luc is also the founder and president of Eusera, an antibody manufacturing company in Edmonton, AB, which designs and produces many commercially successful antibodies.
John Mackey - Co-founder and CMO
John is a medical oncologist and Director, Clinical Trials Unit at the Cross Cancer Institute, Professor of Oncology, University of Alberta, and Chair of the Alberta Pre-Phase I Cancer Program (www.prephaseone.com). As Executive Director of Translational Research In Oncology (TRIO), a global clinical trial company with its head office in Edmonton, he has access to clinical trial operations and samples to facilitate the clinical evaluation of diagnostic and therapeutic agents arising from these investigations. John has a strong network among the end-users of Pacylex’s technology and pharmaceutical partners. You can reach John at email@example.com
Ryan Heit - Co-founder and COO
Ryan has a diverse background in research, technology commercialization, business development, and financing early stage companies. Ryan has provided business planning and company development for many early-stage, technology-based ventures in health-related fields in his position at TEC Edmonton and as an independent consultant. Additionally, he has helped multiple Alberta companies in obtaining financing in his role with the angel investing network, TEC VA. He received his Masters in Experimental Oncology and his Masters of Business Administration with a specialization in Technology Commercialization from the University of Alberta. You can reach Ryan at firstname.lastname@example.org